New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:59 EDTRHT, MTOR, ARWR, SWHC, PIR, VRTX, JBL, BBRY, SBGI, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ARWR SBGI PIR MTOR BBRY SWHC RHT JBL
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 17, 2015
16:10 EDTJBLJabil Circuit backs FY15 Core EPS view of $2.00 per share, consensus $2.02
Backs FY15 revenue guidance of up 13%. "We’re on track to deliver approximately 13% revenue growth and $2.00 in core EPS for this fiscal year, all while continuing to invest for future growth - quite an accomplishment when one considers the current macro environment,” CEO Mark Mondello said. Management updated its FY15 revenue outlook of $17.7B- $17.9B and core EPS of $1.95-$2.05.
16:06 EDTJBLJabil Circuit reports Q3 Core EPS 49c, consensus 49c
Subscribe for More Information
16:05 EDTJBLJabil Circuit sees Q4 core EPS 40c-50c, consensus 47c
Sees Q4 revenue $4.45B-$4.65B, consensus $4.74B.
16:04 EDTJBLJabil Circuit reports Q3 EPS 37c, consensus 49c
Reports Q3 revenue $4.36B, consensus $4.46B.
15:16 EDTPIR, JBLNotable companies reporting after market close
Subscribe for More Information
15:16 EDTPIR, JBLOptions with increasing volume
Subscribe for More Information
14:48 EDTJBLJabil Circuit June 24 straddle priced for 5.6% movement into Q3
Subscribe for More Information
14:33 EDTPIRPier 1 Imports technical notes before earnings news
Subscribe for More Information
14:11 EDTJBLJabil Circuit technical comments ahead of results
The $25 area is one that has proved nearly insurmountable resistance for the shares over the prior five years. With the stock close to that level ahead of earnings, the risk is that it will act as a hard ceiling yet again. If the news is bearish, the uptrend that began last October could be put at risk. The first important test of support would come at the 50-day moving average at $23.86. A breakdown below it would see next support at $22.73, $21.99, and $20.73. If the news is strongly bullish, it is possible that the $25 level could be taken out on the upside. Next resistance above $25 would be at $26.80 and then at $27.40. Both of those levels were the brief highs in 2012. The $30.50 level would be next major resistance if $27.40 were taken out on the upside.
07:36 EDTARWRArrowhead receives regulatory clearance for additional Phase 2b ARC-520 studies
Arrowhead Research announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection, has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are expected shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies. The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1. For each patient, the duration of the study is approximately 33 weeks, from screening to the Day 169 follow-up visit. For each study, a planning interim analysis will be performed when 54 patients have completed their Day 71 visit. This analysis will be used to plan future studies only and will not impact the enrollment or conduct of Heparc-2002 and -2003. Based on the interim results, the company will decide whether higher multiple-doses would be likely to lead to increased activity, in which case higher doses may be evaluated in one or more additional studies. The primary objective of the 2002 and 2003 studies is to evaluate the depth of hepatitis B surface antigen decline in response to multiple doses of ARC-520 compared to placebo as a measure of drug activity. Secondary objectives include the assessment of safety and tolerability and multi-dose pharmacokinetics of ARC-520 when co-administered with entecavir or tenofovir, in addition to other exploratory objectives.
June 16, 2015
15:38 EDTBBRYLenovo executive comments on potential BlackBerry acquisition, BNN says
Subscribe for More Information
14:51 EDTPIRPier 1 Imports June volatility elevated into Q1 and outlook
Pier 1 Imports June call option implied volatility is at 120, July is at 54, September is at 41; compared to its 52-week range 28 to 62, suggesting large June price movement into the expected release of Q1 results on June 17.
12:40 EDTJBLJabil Circuit June volatility increases into Q3 and outlook
Subscribe for More Information
09:36 EDTBBRYActive equity options trading on open
Subscribe for More Information
09:04 EDTRHTSilicon Graphics signs OEM agreement with Red Hat
Subscribe for More Information
June 15, 2015
10:00 EDTJBLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alleghany (Y) upgraded to Buy from Neutral at Janney Capital... BHP Billiton (BHP) upgraded to Hold from Reduce at HSBC... CNOOC (CEO) upgraded to Hold from Underperform at Jefferies... Diageo (DEO) upgraded to Outperform from Underperform at RBC Capital... Jabil Circuit (JBL) upgraded to Buy from Hold at Needham... LRR Energy (LRE) upgraded to Buy from Hold at Wunderlich... Lowe's (LOW) upgraded on positive catalysts at Wedbush... ORBCOMM (ORBC) upgraded to Outperform from Market Perform at Northland... Petrobras (PBR) upgraded to Overweight from Neutral at JPMorgan... Vanguard Natural (VNR) upgraded to Buy from Hold at Wunderlich... Williams-Sonoma (WSM) upgraded on more positive leverage outlook at Wedbush.
07:46 EDTJBLJabil Circuit upgraded to Buy on continued growth at Needham
Subscribe for More Information
07:35 EDTJBLJabil Circuit upgraded to Buy from Hold at Needham
Subscribe for More Information
07:07 EDTSBGICourt of appeals denies NAB incentive auction petition
Subscribe for More Information
05:59 EDTBBRYStocks with implied volatility above IV index mean; TWTR BBRY
Stocks with implied volatility above IV index mean; Twitter (TWTR) 32, BlackBerry (BBRY) 51 according to iVolatility.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use